Aspirin resistance is an important clinical entity that may attenuate the cardiovascular benefits of aspirin therapy, requiring identification and potential alternative therapeutic strategies.
Does not support routine resistance testing or regimen changes; leaves open its prognostic impact pending prospective trials.
Aspirin is the most widely used medication in patients with cardiovascular disease. It has had a greater effect on patients with cardiovascular disease than any other drug. With the importance of aspirin now known for decades, it is recently becoming clearer that some patients do not derive as great a benefit from this "wonder drug" secondary to their resistance to its effects. Aspirin resistance, its prevalence, its identification, and how to overcome or avert it with other medications then becomes a central topic of discussion as important, if not more so, than the importance of aspirin itself as a cornerstone in the treatment of patients with cardiovascular disease. This review explores the current understanding of the mechanism of aspirin resistance with regard to its prevalence and the magnitude of its clinical significance. It also examines the therapeutic implications of a diagnosis of aspirin resistance.
No takes yet. Share an insight, caveat, or question.
Amgad N. Makaryus (2006) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: